Cashu | News | IBRX

HomeWatchlistNewsSignalsPicks

DJI

+0.37%

SPX

+0.49%

IXIC

+0.71%

FTSE

-0.12%

N225

0.00%

AXJO

0.00%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest ImmunityBio News

Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

Feature Image for interests on Biotechnology, Health Care & Hospitals, Healthcare, Investments Opinions from prnewswire.com

Four meme stocks with high social activity and hedge funds shorts, according to JPMorgan

Feature Image for interests on Consumer Cyclical, Financial Services, Healthcare, Investment Strategy from cnbc.com

What's Going On With ImmunityBio Shares Tuesday?

Feature Image for interests on Healthcare, Movers, News, Stock from benzinga.com

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper

Feature Image for interests on Healthcare, News, Stock, Unknown Sector from benzinga.com

Stocks making the biggest moves midday: D-Wave Quantum, Moderna, Agilysys, Tesla and more

Feature Image for interests on Basic Materials, Breaking News: Markets, Business, Consumer Cyclical from cnbc.com

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

Feature Image for interests on Benzinga, Biotech, Briefs, Fda from benzinga.com

Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Feature Image for interests on Basic Materials, Benzinga, Big Losers, Cna from benzinga.com

businesswire.com

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feature Image for interests on Healthcare, Stock, Technology from businesswire.com

businesswire.com

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feature Image for interests on Healthcare, Stock, Technology from businesswire.com

businesswire.com

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Feature Image for interests on Healthcare, Stock, Technology, United Kingdom from businesswire.com

Stocks

Health Care

ibrx

ImmunityBio

NASDAQ: IBRX

-0.12 (-4.21%)

2.73

USD

At close at Sep 19, 20:39 UTC

Latest Cashu News

ImmunityBio and Oncolytics Biotech Propel Cancer Treatment Forward with GOBLET Study Advances

ImmunityBio: Oncolytics Biotech's GOBLET Study Shows Promise in Cancer Treatment Advancements

ImmunityBio Attracts Retail Investor Interest Amid Meme Stock Surge